Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells

C Tekle1,4, E Giovannetti1,2,4, J Sigmond1, JR Graff3, K Smid1 and GJ Peters8,1
1Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands; 2Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Italy; 3Eli Lilly & Co, Indianapolis, IN, USA

Conventional regimens have limited impact against non-small cell lung cancer (NSCLC). Current research is focusing on multiple pathways as potential targets, and this study investigated molecular mechanisms underlying the combination of the PKCβ inhibitor enzastaurin with the multitargeted antifolate pemetrexed in the NSCLC cells SW1573 and A549. Pharmacologic interaction was studied using the combination-index method, while cell cycle, apoptosis induction, VEGF secretion and ERK1/2 and Akt phosphorylation were studied by flow cytometry and ELISAs. Reverse transcription—PCR, western blot and activity assays were performed to assess whether enzastaurin influenced thymidylate synthase (TS) and the expression of multiple targets involved in cancer signaling and cell cycle distribution. Enzastaurin-pemetrexed combination was highly synergistic and significantly increased apoptosis. Enzastaurin reduced both phosphoCdc25C, resulting in G2/M checkpoint abrogation and apoptosis induction in pemetrexed-damaged cells, and GSK3β and Akt phosphorylation, which was additionally reduced by drug combination (~58% in A549). Enzastaurin also significantly reduced pemetrexed-induced upregulation of TS expression, possibly through E2F-1 reduction, whereas the combination decreased TS in situ activity (>50% in both cell lines) and VEGF secretion. The effects of enzastaurin on signaling pathways involved in cell cycle control, apoptosis and angiogenesis, as well as on the expression of genes involved in pemetrexed activity provide a strong experimental basis to their evaluation as pharmacodynamic markers in clinical trials of enzastaurin-pemetrexed combination in NSCLC patients.

British Journal of Cancer (2008) 99, 750–759. doi:10.1038/sj.bjc.6604566 www.bjcancer.com
Published online 19 August 2008 © 2008 Cancer Research UK

Keywords: enzastaurin; protein kinase Cβ; pemetrexed; cell signalling; non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is one of the most commonly occurring malignancies worldwide for which platinum-based regimens are standard first-line treatment (Buter and Giaccone, 2005). However, the dose-limiting toxicity profile of these regimens, as well as response rates not exceeding 40%, warrant novel strategies and new combination regimens against NSCLC.

The multitargeted antifolate pemetrexed is approved as a single agent in second-line treatment of patients with locally advanced or metastatic NSCLC after earlier chemotherapy (Hanna et al., 2004). It inhibits three of the enzymes essential for purine and pyrimidine synthesis; dihydrofolate reductase (DHFR), glycaminide ribonucleotide formyl transferase, and thymidylate synthase (TS), the latter being the most important target (Hanauske et al., 2001). However, resistance to pemetrexed may develop (Peters et al., 2005), and hence combinations with other anticancer agents are important to investigate.

Enzastaurin, a novel targeted agent, selectively inhibits PKCβ by interacting competitively at its ATP-binding site (Faul et al., 2003). Because of its pivotal role in the regulation of tumour-induced angiogenesis, cell cycle progression, tumour cell proliferation, survival, and tumour invasiveness, PKCβ is recognised as an important target for cancer treatment (Goekjian and Jirousek, 2001; Liu et al., 2004). Enzastaurin was originally evaluated in human xenograft-bearing mice for its antiangiogenic activity upon PKCβ inhibition, as it showed reduction of plasma VEGF levels together with a significant decrease in intratumoural vessel density (Keyes et al., 2004). However, several studies have shown that enzastaurin exhibits direct growth inhibiting effects on a wide array of cultured human tumour cells (Graff et al., 2005; Oberschmidt et al., 2005; Querfeld et al., 2006; Rizvi et al., 2006; Podar et al., 2007; Spalding et al., 2007; Lee et al., 2008). Recent studies suggest that the antitumour effects of enzastaurin are mediated through interference with the phosphatidylinositol 3-kinase (PI3K)/Akt pathway (Graff et al., 2005; Querfeld et al., 2006; Rizvi et al., 2006; Lee et al., 2008), an important pathway regulating the apoptotic response.

The advantage of enzastaurin and other targeted agents is that they can act selectively on inappropriately expressed or overexpressed molecules in cancer signaling pathways. Overexpression of different PKC isoforms has been detected in NSCLC cells and...
tumour tissues (Clark et al, 2003; Lahn et al, 2006), whereas activation of Akt was associated with significantly worse 5-year survival rate in NSCLC patients (Tang et al, 2006).

Currently enzastaurin is being evaluated in several clinical trials and tolerability and survival data obtained in a recent phase II trial as second- or third-line therapy in NSCLC suggest further evaluation in combination with cytotoxic drugs (Oh et al, 2008). Indeed other studies have demonstrated the safety of enzastaurin combination with conventional chemotherapy (Hanauske et al, 2006; Rademaker-Lakhai et al, 2007), and the inhibition of selected targets, including PKCβ, can enhance the effect of cytotoxic drugs, such as pemetrexed. Previous studies showed positive synergism for this combination in thyroid and lung cancer cell lines (Oberschmidt et al, 2005; Nakajima et al, 2006), but data on possible molecular mechanisms or biomarkers of that combination are still lacking.

The aim of this study was to investigate the main pharmacological aspects of the enzastaurin-pemetrexed combination in NSCLC cells. For this purpose the potential synergistic interaction, as well as the responsible mechanisms were studied.

MATERIALS AND METHODS

Drugs and chemicals

Both pemetrexed and enzastaurin were provided by Eli Lilly Corporation (Indianapolis, IN, USA). The drugs were dissolved in Hanks’ balanced salt solution and Dimethyl Sulphoxide (DMSO) respectively, stored at 20°C, and diluted in culture medium immediately before use. (5-3H)-Deoxycytidine and (5-3H)-DeoxyUMP were from Moravek Biochemicals (Brea, CA, USA). All other chemicals were of analytical grade.

Cells and culture conditions

The NSCLC cell lines A549 (adenocarcinoma) and SW1573 (alveolar carcinoma) were from American Type Culture Collection (ATCC) (Manassas, VA, USA), and were cultured in Dulbecco’s modified Eagle’s medium (Flow Laboratories Irvine, Scotland), supplemented with 10% heat-inactivated Fetal calf serum, 20 mM 4-(2-Hydroxyethyl)-1-piperazinyl)-ethanesulphonic acid, and 1% penicillin–streptomycin (Gibco Paisley, UK), at 37°C in an atmosphere of 5% CO2. The cells were maintained in 75 cm2 tissue culture flasks (Greiner Bio-One GmbH, Frickenhausen, Germany) and were harvested with trypsin-EDTA (Invitrogen, Paisley, UK) in a carbon dioxide atmosphere of 5% CO2. The cells were maintained in 75 cm2 tissue culture flasks (Greiner Bio-One GmbH, Frickenhausen, Germany) and were harvested with trypsin-EDTA (Invitrogen, Paisley, UK) in their exponentially growing phase.

Growth inhibition and drug combination studies

Growth inhibitory effects of pemetrexed and enzastaurin were evaluated with the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, which measures mitochondrial activity of viable cells. Both cell lines (3000 cells per well) were plated into flat bottom 96-well plates (Greiner Bio-One GmbH, Germany) and allowed to attach for 24 h. The cells were treated for 72 h as follows: (1) a concentration range (0.01 – 100 μM) of each drug was tested for the IC50 value; (2) simultaneous combination of the two drugs using a fixed IC50-based molar ratio; (3) simultaneous combination using a variable ratio (with constant IC50 concentration of enzastaurin); (4) sequential combination using a variable ratio. After treatment, the medium was removed and cells were incubated for 3 h at 37°C in 50 μl per well MTT solution (final concentration 0.42 mg ml−1). Formazan crystals formed were dissolved in 150 μl per well DMSO and the absorbance was measured at 540 nm using a spectrophotometric microplate reader (Tecan Spectrafluor, Salzburg, Austria). Absorbance values were corrected for the absorbance at the day of drug administration, which was taken as 0%, the difference with untreated controls was set at 100%, and the effect of drugs as a percentage thereof. The 50% inhibitory concentration of cell growth was estimated from the logarithmic growth inhibition curves.

The pharmacological interaction of enzastaurin and pemetrexed was assessed using the multiple drug effect analysis based on the methods described by Chou and Talalay (1984) in which a Combination Index (CI) <0.9, 0.9–1.1 and >1.1 indicate synergism, additivity and antagonism, respectively. The mean CI was calculated from all data points with fraction affected (FA) >0.5, as values lower were not considered relevant for growth inhibition (Peters et al, 2000). The data were processed by the Calcsyn Software (Biosoft, Cambridge, UK), which calculates the CI of the combination based on the effect of the growth inhibition caused by the drugs alone relative to the effect produced by the combination.

Cell cycle and apoptosis analysis

Flow cytometry was used to determine cell cycle distribution as well as the amount of apoptotic cells within the cell populations exposed to the drugs alone or in combination as described previously (Temmink et al, 2007). Cells at a density of 50 × 103 cells per well were plated into flat bottom 6-well plates (Greiner Bio-One GmbH, Germany) and allowed to attach for 24 h prior to drug treatments at IC50 concentrations. The exposure time ranged from 24–72 h involving both single drug treatments as well as simultaneous combination drug treatments. Subsequently, adherent and floating cells were harvested and counted, and at a concentration of 1 × 105 cells ml−1 transferred to round-bottom FALCON tubes (BD, Franklin Lakes, NJ, USA). After centrifugation, the cell pellets formed were gently resuspended in 1.0 ml hypotonic propidium iodide (PI)-solution (50 μg ml−1 PI, 0.1% sodium citrate, 0.1% Triton X-100, 0.1 mg ml−1 ribonuclease A) and the samples were stored on ice for 30 min. Cell cycle analyses were performed using a FACScan (BD Biosciences, Mount View, CA, USA) and the data analysis was carried out with CELLQuest™ software, using gates on DNA histograms to estimate the amount of cells in G1, S, and G2/M phases, as well as the apoptotic cells in the sub-G1 region.

Real-time PCR

To evaluate the effect of 24-h treatment with IC50 levels of enzastaurin, pemetrexed and their combination on the expression levels of molecules involved in drug activity, cell cycle control and angiogenesis we studied the mRNA expression of TS, E2F-1 and VEGF. RNA was extracted by the QiAamp RNA mini-Kit (Qiagen, Hilden, Germany) and was reversed transcribed. Forward and reverse primers and probes were designed with Primer Express (Applied Biosystems, Foster City, CA, USA) on the basis of TS gene sequence (Giovannetti et al, 2005), whereas primers and probes for E2F-1 and VEGF were obtained from Applied Biosystems Assay-on-Demand Gene expression products (Hs00157299_m1, and Hs00173626_m1). Amplification data were normalised to β-actin, and quantification of gene expression was performed using standard curves obtained with dilutions of cDNA from Quantitative-PCR Human-Reference Total-RNA (Stratagene, La Jolla, CA, USA).

Western blot analysis

Enzastaurin and pemetrexed and their combination were also studied for their ability to modulate protein expression of different possible targets or surrogate markers of drug activity by western blot analyses. Frozen pellets of A549 and SW1573 cells previously treated with IC50 concentrations of pemetrexed and enzastaurin (single and in the simultaneous combination) for 24 h were resuspended in a lysis buffer (0.1% (v/v) Triton X-100, 10%...
RESULTS

Growth inhibition studies of pemetrexed and enzastaurin

A dose-dependent inhibition of cell growth was observed with pemetrexed and enzastaurin (Figure 1), with IC_{50} values of 0.05 and 21.75 μM (SW1573) and 0.19 and 8.83 μM (A549), respectively (Table 1). As the CI method recommends a ratio of concentrations at which drugs are equipotent, the following combination studies were performed using fixed ratios with IC_{50} values calculated from the previous cytotoxicity analysis for the different drug treatments in each cell line (i.e., 1 : 50 and 1 : 450 in A549 and SW1573 cells, respectively). However, as enzastaurin is administered orally (Carducci et al, 2006) and reaches a relatively stable plasma concentration for a prolonged time, we also used enzastaurin at a fixed IC_{25} concentration in simultaneous combination in both cell lines and in the sequential combination in the less sensitive SW1573 cells.

**Figure 1** Cytotoxicity and pharmacological interaction of enzastaurin and pemetrexed. Representative curves of growth inhibitory effects of pemetrexed and sequential (24-h enzastaurin followed by 48-h pemetrexed) drug combination (A) and simultaneous enzastaurin-pemetrexed combination (B) in SW1573 cells, using a variable ratio (with constant IC_{25} concentration of enzastaurin). Points and columns, mean values obtained from three independent experiments; bars, s.e.
Both the simultaneous and the sequential combination reduced the IC50 values of pemetrexed in the studied cell lines. Representative growth inhibition curves for SW1573 cells are shown in Figure 1A and B. The multiple drug effect analysis revealed strong synergistic effects in the simultaneous treatment as well as in the sequential schedule. In particular, the CI plots of simultaneous combination in both cells showed a clear synergistic interaction at the more relevant FA values (≥50%). The average CI values for enzastaurin-pemetrexed combinations in the two NSCLC cell lines are summarised in Table 1.

To evaluate the mechanisms underlying the synergistic interaction in both cell lines, several biochemical analyses were performed with the simultaneous combination, as detailed below.

**Cell cycle distribution**

DNA flow cytometry studies were performed to evaluate the effect of enzastaurin, pemetrexed and their combinations on the cell cycle distribution and to determine whether their cell cycle modulating activity might provide clues to optimise drug scheduling. Both agents were able to affect the cell cycle of the studied NSCLC cells (Figure 2A and B).

Pemetrexed treatment resulted in a 1.3 to 1.9-fold increase in the percentage of cells in the S-phase after 24 h in SW1573 and A549 cells, respectively. The increment in S-phase was most pronounced after 72 h, with 37 and 39% of the SW1573 and A549 cells arrested in the S-phase. In contrast, the 24 h enzastaurin treatment caused minimal perturbations in the A549 cells, and a 1.3-fold increase in the percentage of SW1573 cells in the G2/M phase. In both cell lines enzastaurin led to 1.3-fold increase in the G1 phase at 72 h. However, the simultaneous combination at 72 h resulted in a G2/M phase increase in both cell lines. In particular, the increase in the G2/M phase cell population was most pronounced in A549 cells (from 25 to 43% in control and treated cells respectively), whereas SW1573 cells showed a 1.5-fold enhancement.

**Apoptosis**

The extent of apoptosis induction was investigated as the accumulation of cells with sub-G1 DNA content in FACS analysis, and was time-dependent in both cell lines, with minimal changes at 24 h. After 72 h enzastaurin slightly increased the percentage of apoptotic cells in SW1573 cells (Figure 2C), whereas a significant increase with respect to control was observed in A549 cells (Figure 2D). Pemetrexed induced more apoptosis than enzastaurin in both cell lines, ranging from 10.8 to 14.0% in SW1573 and A549 cells, respectively (P<0.01 vs control). The combination showed a more than additive cell kill with respect to the single drugs and a significant induction in apoptosis compared with both controls and pemetrexed-treated cells (P<0.001 vs control and P<0.05 vs pemetrexed).

**Modulation of signal transduction**

Since enzastaurin affects several intracellular signaling cascades, we initially focused on expression of different proteins down-
Enzastaurin and pemetrexed in non-small cell lung cancer
C Tekle et al

Modulation of cell signaling pathways. (A) Modulation of protein expression of different targets involved in cell signaling pathways by enzastaurin, pemetrexed and their simultaneous combination (24 h to IC50 values). The western blots shown are representative of 2–3 separate experiments, loading 20 μg protein. Modulation of Akt (B), and ERK1/2 (C) phosphorylation by enzastaurin, pemetrexed and their simultaneous combination, for 24 h, at IC50 values, in NSCLC cells, as determined with ELISA assays. Columns, mean values obtained from three independent experiments; bars, s.e. *Significantly different from controls (P < 0.05).

PKC activation can also trigger signaling through the ERK pathway, which may also be involved in the control of cellular proliferation and death. Enzastaurin resulted in a significant inhibition of pERK1/2 in both cell lines, whereas pemetrexed slightly increased ERK1/2 phosphorylation (Figure 3B). A reduction of phospho-ERK1/2, less pronounced than the one observed with enzastaurin alone, but still significant with respect to controls, was also detected after the drug combination.

Modulation of cell cycle proteins and TS

As PKCs regulate cell cycle progression by phosphorylation (directly or indirectly) of cell cycle-dependent kinases and transcription factors, we evaluated the expression of several of these proteins by western blot analysis (Figure 4A). Our findings suggest that enzastaurin might affect the cell cycle at both the G2/M and G1/S checkpoints. In particular, enzastaurin resulted in a marked decrease of both total and phosphorylated Cdc25C in both cell lines, as shown in a representative example in Figure 4A. The dephosphorylation of Cdc25C induces G2/M transition. Hence, enzastaurin treatment might abrogate the G2/M checkpoint. Consequently, cells with DNA damage (due to pemetrexed treatment) can progress in the cell cycle and eventually undergo apoptosis.

Modulation of cell cycle proteins and TS

As PKCs regulate cell cycle progression by phosphorylation (directly or indirectly) of cell cycle-dependent kinases and transcription factors, we evaluated the expression of several of these proteins by western blot analysis (Figure 4A). Our findings suggest that enzastaurin might affect the cell cycle at both the G2/M and G1/S checkpoints. In particular, enzastaurin resulted in a marked decrease of both total and phosphorylated Cdc25C in both cell lines, as shown in a representative example in Figure 4A. The dephosphorylation of Cdc25C induces G2/M transition. Hence, enzastaurin treatment might abrogate the G2/M checkpoint. Consequently, cells with DNA damage (due to pemetrexed treatment) can progress in the cell cycle and eventually undergo apoptosis.
Enzastaurin did not affect CDK2 and CDK4 (data not shown), but was able to downregulate the G1/S checkpoint. Indeed, our results suggest that enzastaurin has a direct effect on E2F-1, which regulate in turn the transcription of several genes, including TS. E2F-1 mRNA expression was significantly reduced by enzastaurin treatment, whereas pemetrexed increased E2F-1 mRNA levels (Figure 4B). However, a significant reduction of E2F-1 mRNA expression was also detected after the drug combination in both cell lines. These results were consistent with those of Figure 4A, showing that pemetrexed increased E2F-1 protein expression, whereas E2F-1 protein levels were significantly reduced by enzastaurin and the enzastaurin-pemetrexed combination. 

TS expression in the different combinations were evaluated by western blotting analysis, which revealed that enzastaurin and the enzastaurin-pemetrexed combination caused a significant reduction in TS mRNA, whereas pemetrexed markedly increased TS mRNA (Figure 4B). However, a significant reduction in TS mRNA expression was also detected after enzastaurin-pemetrexed simultaneous combination in A549 cells, whereas a lower degree of inhibition (~28%) was detected in SW1573 cells. Thymidylate synthase expression was also studied at the protein level, by western blotting analysis, which revealed that enzastaurin and pemetrexed affected TS protein expression in both NSCLC cells (Figure 4A). In particular, a strong induction was detected in A549 and SW1573 pemetrexed-treated cells, whereas the faintest bands were observed in the extracts of enzastaurin-treated cells. Furthermore, enzastaurin was able to reduce the upregulation of TS caused by pemetrexed, as detected in the cells treated with the enzastaurin-pemetrexed combination.

As protein expression of TS is not always predictive for the real enzymatic activity in the cells, we then evaluated TS activity by the TS in situ assay, in which intact cells are used, and the drugs are still present in the cells, resulting in an actual measurement of real intracellular TS inhibition (Figure 4C). This assay showed a clear inhibition of TS by pemetrexed and enzastaurin in both cell lines. Most interestingly, the combination almost completely inhibited the TS activity in situ (i.e., 13 ± 2 and 9 ± 4% in SW1573 and A549 cells, respectively) and statistical analysis revealed significant reductions with respect to those observed after pemetrexed exposure. Direct inhibition of TS activity by nzastaurin was excluded as addition of enzastaurin up to 50 μM did not inhibit TS activity in extracts of both cell lines, whereas FdUMP and pemetrexed, used as a control, showed similar inhibition as reported earlier (Van Triest et al., 1999).

Effects on COX-2 and VEGF

As enzastaurin has been reported to have an anti-VEGF effect we evaluated the expression of possible markers of antiangiogenic activity both in cells and in cell culture medium. In this study, we investigated the expression level of the pro-angiogenic factor COX-2 to determine whether it could serve as a reliable marker of the antiangiogenic effect of enzastaurin in NSCLC cells. However, no expression of COX-2 was found in the SW1573 cell line. Furthermore in the A549 cells the expression levels were still elevated after drug exposure, indicating that the antiangiogenic effects of enzastaurin might not be because of modulation of the COX-2 enzyme in the studied cell lines (Figure 5A).

On the other hand, enzastaurin significantly decreased both VEGF mRNA expression and VEGF secretion into the medium. Pemetrexed induced a slight increase of VEGF expression (Figure 5B and C). However, the combination induced a significant inhibition of VEGF expression. In line with this, VEGF secretion was significantly reduced after enzastaurin-pemetrexed combination in both cell lines (Figure 5C).

DISCUSSION

In this study we found that the interaction between enzastaurin and pemetrexed was highly synergistic in NSCLC cells. These results are in agreement with previous data obtained with pemetrexed-enzastaurin combination both in lung and in thyroid cancer cells (Oberschmidt et al., 2005).

The synergistic activity of enzastaurin was detected in all the studied combinations, at concentrations similar to those achieved in clinical trials (Rademaker-Lakhai et al., 2007).

These findings are of importance as pemetrexed is already registered for treatment of NSCLC, and enzastaurin might be a promising agent to improve the effect of pemetrexed in NSCLC patients, possibly as an alternative to cisplatin regimens. Unlike EGFR-tyrosine kinase inhibitors, antiangiogenic agents combined with conventional chemotherapy have demonstrated clinical benefit in NSCLC (Herbst et al., 2007), and recent studies have demonstrated the safety of enzastaurin combination with cytotoxic drugs (Rademaker-Lakhai et al., 2007), including pemetrexed (Hanauske et al., 2006).

Furthermore, our findings are novel because they show that the synergistic interaction seems to be mediated by several mechanisms, summarised in Figure 6, which enhanced the sensitivity to pemetrexed and should be used as predictive biomarkers for the future clinical development of enzastaurin-pemetrexed combination.

Several studies have shown the importance of modulating the cell cycle to exploit the effect of drug combinations (Schwartz and Shah, 2005). Drugs interacting at different sites in the cell cycle might potentiate the therapeutic response. In this study, FACS analysis demonstrated that pemetrexed caused a S-phase arrest, as previously detected in different tumour cell lines (Tonkinson et al., 1997, 1999; Giovannetti et al., 2005). In contrast, enzastaurin alone increased the percentage of cells in the G1 phase, whereas in the combination the cells accumulated in G2/M phase. These results are in agreement with previous studies showing that PKCs modulate the cell cycle (Fishman et al., 1998; Black et al., 2000). In particular, the phosphorylation mediated by PKC might activate Cdc25C, which is an important control component of the G2/M checkpoint (Yu et al., 2004). This inhibits transition into mitosis, as phosphorylated Cdc25C is not able to activate its downstream targets and the cells become arrested at this checkpoint. This arrest prevents DNA damaged cells to cycle further and represents a survival mechanism that provides the tumour cells the opportunity to repair their damaged DNA (Houtgraaf et al., 2006). Therefore the reduction of phosphoCdc25C by enzastaurin, as detected by western blot analysis, might explain the abrogation of the G2/M checkpoint and the synergistic induction of apoptosis in the enzastaurin-pemetrexed combination. Indeed, pemetrexed is able to damage the DNA because of incomplete replication (Backus et al., 2000), which can lead to arrest of the cells at the checkpoints controlling the cell cycle. Thus, when combining these two agents, enzastaurin can facilitate pemetrexed-damaged cells to undergo apoptosis. In line with our observations, previous studies showed little effects of enzastaurin alone on cell cycle progression (Lee et al., 2008), but others reported that the non-selective PKC inhibitor UCN-01 was able to inhibit the phosphorylation of Cdc25C and abrogate the G2/M checkpoint, potentiating the cytotoxicity of a variety of anticancer agents (Yu et al., 1998; Graves et al., 2000).

However, enzastaurin was also able to influence other proteins involved in cell cycle regulation. In particular, the G1/S checkpoint is, among other proteins, governed by the S-phase regulator E2F-1,
whose mRNA and protein expression was significantly reduced by both enzastaurin and enzastaurin-pemetrexed treatment. These results may be related to the inhibition of the Ras/MAPK/ERK-dependent pathway, which is implicated in the modulation of the expression of the cyclin D1 gene. Recent studies showed controversial results on the effects of enzastaurin on ERK pathway in different tumour cell lines (Guo et al., 2008; Lee et al., 2008). However, cyclin D1 protein expression was reduced after 24 h exposure at IC_{50} values of UCN-01 (Akiyama et al., 1997) and cyclin D1 downregulation results in E2F-1 inhibition (Kobayashi et al., 2006). Furthermore, UCN-01 induced the accumulation of underphosphorylated pRb (the dephosphorylated retinoblastoma protein form), which prevented the release of free E2F-1 (Akiyama et al., 1997).

E2F-1 is a critical upstream transcriptional regulator of several genes, including TS and DHFR (Li et al., 2006). Expression levels of TS were associated with E2F-1 expression in NSCLC cells and samples (Huang et al., 2007; Giovannetti et al., 2008).

Several studies showed that TS expression is significantly correlated with pemetrexed sensitivity both in the preclinical and in the clinical setting (Giovannetti et al., 2005; Gomez et al., 2006). Therefore, the reduction of E2F-1 expression, leading to a decreased amount of TS, can potentiate pemetrexed activity in the enzastaurin-treated cells. TS, as an RNA-binding protein, also regulates its own synthesis by impairing the translation of its mRNA, whereas the binding to a specific inhibitor leads to upregulation of TS protein (Chu et al., 1991). In agreement with this hypothesis, as well as with the observed increase in TS mRNA expression, as previously detected with pemetrexed and 5-fluorouracil (5-FU) (Peters et al., 2002; Mauritz et al., 2007), TS protein expression in cell extracts was enhanced after pemetrexed exposure. However, this study also shows that enzastaurin-pemetrexed combination significantly inhibited the activity of TS, potentially leading to synergistic drug interaction. These results are in agreement with previous data demonstrating that UCN-01 was able to enhance the activity of 5-FU through downregulation of TS (Hsu et al., 1998; Abe et al., 2000).

Enzastaurin also reduced the phosphorylation of the downstream PKC/β-signaling pathway effectors Akt and GSK3β; these findings are consistent with several previous reports in different cancer cell lines, xenografts and peripheral blood mononuclear cells (PBMCs) (Graff et al., 2005; Querfeld et al., 2006; Rizvi et al., 2006), suggesting the use of GSK3β phosphorylation in PBMCs as a pharmacodynamic marker for enzastaurin (Graff et al., 2005). Our experiments showed that the Akt pathway can also be affected by pemetrexed, as reported previously (Giovannetti et al., 2005, 2008).

In addition, the enzastaurin-pemetrexed combination significantly reduced Akt phosphorylation, which may explain the increased apoptosis found in the pemetrexed-erlotinib combination in the studied NSCLC cell lines.

Although recent preclinical studies have shown that enzastaurin has a direct effect on several human cancer cells, tumour xenograft models (Graff et al., 2005; Lee et al., 2008), and also patient-derived tumour explants (Hanauske et al., 2007), enzastaurin was initially developed for its striking antiangiogenic activity. In particular, enzastaurin significantly decreased intratumoural vessels density and VEGF expression in different human tumour xenografts (Keyes et al., 2004). Similarly, a recent study showed a significant

Figure 5  Antiangiogenic effects. Effects of pemetrexed, enzastaurin and their simultaneous combination on COX-2 expression (A), as detected by western blot analysis, and on VEGF mRNA expression (B) and secretion in cell culture medium (C) of SW1573 and A549 cells, as detected by PCR and ELISA assay, respectively. Columns (%), mean values obtained from three independent experiments; bars, s.e.; *P<0.05 with respect to control cells.
Figure 6  Molecular signaling pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with pemetrexed. Enzastaurin enhanced the growth inhibitory effects of pemetrexed through its pronounced anti-signaling effects downstream of PKCβ. Moreover, the modulation of cell cycle regulating proteins enhanced both apoptosis induction and pemetrexed-mediated TS enzyme inhibition.

**REFERENCES**

Abé S, Kubota T, Otani Y, Furukawa T, Watanabe M, Kumai K, Kitajima M (2000) UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA. *Jpn J Cancer Res* 91: 1192–1198

Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M, Akinaga S (1997) G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. *Cancer Res* 57: 1495–1501

Backus HH, Pinedo HM, Wouters D, Kuiper CM, Jansen G, Van Groeningen CJ, Peters GJ (2000) Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. *Oncol Res* 12: 231–239

Black JD (2000) Protein kinase C-mediated regulation of the cell cycle. *Front Biosci* 5: D406–D423

Buter J, Giaccone G (2005) Medical treatment of non-small-cell lung cancer. *Ann Oncol* 16(Suppl 2): ii229–ii232

Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS (2006) Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. *J Clin Oncol* 24: 4092–4099

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv Enzyme Regul* 22: 27–55

Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S, Allegra CJ (1991) Autoregulation of human thymidylate synthase

Reduction of VEGF protein levels, as well as a reduction of VEGF induction by radiotherapy, in the supernatants of glioma cells exposed for 24 h to enzastaurin (Tabatabai et al., 2007). Likewise in our study enzastaurin significantly decreased both VEGF mRNA expression and VEGF secretion into the medium. Furthermore, despite the slight increase of VEGF expression induced by pemetrexed, the enzastaurin-pemetrexed combination resulted in a significant inhibition of VEGF expression, possibly leading to reduced secretion of VEGF. The mechanism of this decrease was postulated to be related to COX-2, as a strong correlation between COX-2 and VEGF mRNA was reported in NSCLC patients (Yuan et al., 2005). However, in SW1573 no COX-2 expression was detected, whereas in A549 cells COX-2 levels increased. Hence, VEGF decrease might be related to other factors, as reported earlier in A549 xenograft tumour tissues (Shaik et al., 2006). In a clinical study performed in our institution enzastaurin reduced VEGF plasma levels (Peters et al., 2007). However, a recent clinical trial in advanced NSCLC patients treated with enzastaurin did not show a consistent change in plasma VEGF levels, but low baseline VEGF levels were associated with longer progression-free survival (Oh et al., 2008). Therefore, future studies are warranted to determine whether VEGF levels can be used as a predictive marker of the activity of enzastaurin alone or in combination with other anticancer agents.

Finally, other inhibitors of PKCs, such as staurosporine and its analogue UCN-01, have the same properties as enzastaurin when it comes to inhibition of the cell cycle, but are less selective than enzastaurin. This non-selective inhibition of PKCs makes them too toxic and hence their use in the clinical setting seems limited, whereas enzastaurin which is a selective PKCβ inhibitor, has shown to be well-tolerated by patients in clinical trials (Carducci et al., 2006; Oh et al., 2008).

In conclusion, enzastaurin is a very promising anticancer agent, attacking several cellular signaling pathways that are involved in the proliferation, cell cycle control, inhibition of apoptosis and of pro-angiogenic properties of tumour cells. This makes it a good candidate for different combination regimens, including combinations with other novel targeted agents and cytotoxic drugs commonly used in the clinical setting.
Hsueh CT, Kelsen D, Schwartz GK (1998) UCN-01 suppresses thymidylate synthase expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. *Clin Cancer Res* 4: 2201 – 2206

Huang CL, Liu D, Nakano J, Yokomie H, Ueno M, Kadota K, Wada H (2007) E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non-small cell lung cancer. *Clin Cancer Res* 13: 6938 – 6946

Keyes KA, Mann L, Sherman M, Galbreath E, Schirzinger L, Ballard D, Chen YF, Iversen P, Teicher BA (2004) *LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol* 53: 133 – 140

Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B (2006) Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. *Cancer Res* 66: 11389 – 11398

Lahn M, McClelland P, Ballard D, Mintz K, Thornton D, Sandusky G (2006) Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer. *Histopathology* 49: 429 – 431

Lee KW, Kim SG, Kim HP, Kwon E, You J, Choi HJ, Park JH, Kang BC, Im SA, Kim TY, Kim WH, Bang YJ (2008) Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. *Cancer Res* 68: 1916 – 1922

Li W, Xu RJ, Zhang HH, Jiang LH (2006) Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma. *Int J Gynecol Cancer* 16: 1673 – 1678

Liu Y, Su W, Thompson EA, Leitges M, Murray NR, Fields AP (2004) Protein kinase Cβεtallat regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. *J Biol Chem* 279: 45556 – 45563

Mauritz R, van Groeningen CJ, Smid K, Jansen G, Pinedo HM, Peters GJ (2007) Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. *Int J Cancer* 120: 2609 – 2612

Nakajima E, Helfrich B, Chan D, Zhang Z, Hirsch FR, Chen V, Ma D, Bunn PA (2006) Enzastaurin in a protein kinase Cβ-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines. *ASCO Annual Meeting Proceedings* 2006. J Clin Oncol 18S: 13138

Oberschmidt O, Eismann U, Schulz L, Struck S, Blatter J, Lahn MM, Ma D, Hanauske AR (2005) Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro. *Int J Clin Pharmcol Ther* 43: 603 – 604

Oh Y, Herbst RS, Burris H, Cleaverly A, Musib L, Lahn M, Bepler G (2008) Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. *J Clin Oncol* 26: 1135 – 1141

Peters GJ, Backus HH, Freemantle S, van TB, Codacci-Pisanelli G, van der Wilt CL, Van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Peters GJ, Hooiberg JH, Kaspers GJL, Jansen G (2005) Folates and multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. *Cancer Chemother Pharmacol* 53: 1181 – 1186

Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT, Lin BK, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijnen JH, Schellens JH, Voest EE (2007) Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase...
C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 13: 4474 – 4481
Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL, Rosen ST (2006) Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 5: 1783 – 1789
Rots MG, Pieters R, Peters GJ, van Zantwijk CH, Mauritz R, Noordhuis P, Willey JC, Hahlen K, Creutzig U, Janka-Schaub G, Kaspers GJ, Veerman AJ, Jansen G (1999) Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. Blood 94: 3121 – 3128
Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23: 9408 – 9421
Shaik MS, Chatterjee A, Jackson T, Singh M (2006) Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer 118: 396 – 404
Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ (2003) Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 66: 431 – 438
Spalding AC, Watson B, Davis ME, Kim AC, Lawrence TS, Ben-Josef E (2007) Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer. Clin Cancer Res 13: 6827 – 6833
Tabatabai G, Frank B, Wick A, Lemke D, von Kürthy G, Obermuller U, Heckl S, Christ G, Weller M, Wick W (2007) Synergistic antiangiogenesis activity of radiotherapy and enzastaurin. Ann Neurol 61: 153 – 161
Tang JM, He QY, Guo RX, Chang XJ (2006) Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181 – 191
Temmink OH, Prins HJ, van Gelderop E, Peters GJ (2007) The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. Br J Cancer 96: 61 – 66
Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C, Mendelsohn LG (1997) Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 39: 521 – 531
Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG (1999) Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 59: 3671 – 3676
van Triest B, Loftus BM, Pinedo HM, Backus HH, Schoenmakers P, Tellemann T, Aherne GW, van Groeningen CJ, Zoetmulder FA, Taal BG, Johnston PG, Peters GJ (2000) Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody. J Histochem Cytochem 48: 755 – 760
van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Tellemann F, Schoenmakers PS, van der Wilt CL, van Laar JA, Noordhuis P, Jansen G, Peters GJ (1999) Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 5: 643 – 654
Yu BZ, Zheng J, Yu AM, Shi XY, Liu Y, Wu DD, Fu W, Yang J (2004) Effects of protein kinase C on M-phase promoting factor in early development of fertilized mouse eggs. Cell Biochem Funct 22: 291 – 298
Yu L, Orlandi L, Wang P, Orr MS, Senderowicz AM, Sausville EA, Silvestrini R, Watanabe N, Piwnica-Worms H, O’Connor PM (1998) UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. J Biol Chem 273: 33455 – 33464
Yuan A, Yu CJ, Shun CT, Luh KT, Kuo SH, Lee YC, Yang PC (2005) Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 115: 545 – 555